Day One Biopharmaceuticals pany(DAWN) - 2023 Q4 - Annual Results
Day One Biopharmaceuticals pany(US:DAWN)2024-02-25 16:00Exhibit 99.1 Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress PDUFA target action date for tovorafenib NDA in relapsed or progressive pLGG remains set for April 30, 2024 Phase 2 FIREFLY-1 tovorafenib registrational data published in Nature Medicine Ended 2023 with $366.3 million in cash, cash equivalents and short-term investments providing runway into 2026 BRISBANE, Calif., Feb. 26, 2024 – Day One Biopharmaceuticals (Nasdaq: DAWN) ("Day One" or the "Company"), a cl ...